Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 104 matching trials from the live ClinicalTrials.gov search.
Terminated No phase listed Observational Accepts healthy volunteers

New Daily Persistent Headache Biomarkers Study

NCT04260087
Conditions
New Daily Persistent Headache, New Daily Persistent Headache (NDPH)
Interventions
Not listed
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Transformed Migraine, Chronic Daily Headache
Interventions
SPG Block with 5% Lidocaine gel, Amitriptyline
Procedure · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Migraine Disorders
Interventions
Botulinum toxin type A Dose 1, Botulinum toxin type A Dose 2, Placebo (Normal Saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years to 17 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Phoenix, Arizona • Fullerton, California • Oceanside, California + 19 more
Conditions
Chronic Migraine
Interventions
Atogepant 30 mg, Atogepant 60 mg, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
41
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 35 more
Conditions
Resistant Migraine, Chronic Migraine Headache, Headache (Migraine), Headache, Cluster
Interventions
Neurostimulator
Device
Lead sponsor
Salvia BioElectronics
Industry
Eligibility
22 Years to 84 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Newnan, Georgia • Olney, Maryland • Charlotte, North Carolina
Withdrawn Not applicable Interventional Accepts healthy volunteers

Aspirin Resistance in Women With Migraine

NCT01257893
Conditions
Episodic Migraine, Chronic Migraine
Interventions
Aspirin (acetylsalicylic acid), Placebo
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Chronic Migraine or Episodic Migraine
Interventions
Placebo, AMG 301
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Long Beach, California • Santa Monica, California • Boulder, Colorado + 18 more
Conditions
Chronic Migraine
Interventions
HD-tDCS Active Protocol, HD-tDCS Sham Protocol
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Phase 2 Interventional Results available

Assessment of LBR-101 In Chronic Migraine

NCT02021773
Conditions
Chronic Migraine
Interventions
LBR-101 High Dose, LBR-101 Low Dose, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
57
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Conditions
Chronic Migraine
Interventions
Galcanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
45
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Conditions
Migraine, Headache, Migraine Disorders, Chronic Migraine, Lifestyle Factors, Headache Disorders
Interventions
Lifestyle Behavior Protocol, Sham Behavior Protocol
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Chronic Migraine
Interventions
Botulinum toxin type A, Placebo
Biological · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

NINDS CRC Chronic Migraine Treatment Trial

NCT00772031
Conditions
Chronic Migraine
Interventions
propranolol LA, topiramate, placebo
Drug
Lead sponsor
Anne Lindblad
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
39
States / cities
Phoenix, Arizona • Tuscon, Arizona • Chico, California + 35 more
Conditions
Migraine
Interventions
Stimulation of the Occipital Nerves
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
8 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
4
States / cities
Newington, New Hampshire • New York, New York • Cincinnati, Ohio + 1 more
Not listed No phase listed Observational Accepts healthy volunteers

Study of Low-dose Naltrexone in Chronic Migraine With Fibromyalgia

NCT05536050
Conditions
Chronic Migraine, Fibromyalgia, New Daily Persistent Headache
Interventions
Migraine diary and Questionnaires
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Chronic Migraine
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
Dent Neuroscience Research Center
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Springfield, Missouri • Reno, Nevada • Amherst, New York + 1 more
Conditions
Chronic Migraine
Interventions
onabotulinumtoxinA, Topiramate, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Springfield, Missouri
Conditions
Migraine Disorders, Chronic Migraine Headache, Migraine
Interventions
Middle Meningeal Artery Embolization
Procedure
Lead sponsor
Cortex Neurovascular
Industry
Eligibility
18 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tacoma, Washington
Conditions
Migraine Disorders
Interventions
Middle Meningeal Artery embolization
Device
Lead sponsor
Cerenovus, Part of DePuy Synthes Products, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Walnut Creek, California • Hartford, Connecticut • Buffalo, New York + 5 more
Conditions
Chronic Migraine Headache
Interventions
NEUROMARK System
Device
Lead sponsor
Neurent Medical
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Birmingham, Alabama • Opelika, Alabama • Los Angeles, California + 4 more
Conditions
Migraine Disorders
Interventions
ALD403 (Eptinezumab), Placebo
Biological
Lead sponsor
Alder Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 65 more
Conditions
Treatment for Prevention of Chronic Migraine
Interventions
Erenumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 66 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
29
States / cities
Newport Beach, California • Palo Alto, California • Santa Monica, California + 25 more
Conditions
Chronic Migraine Without Aura, Intractable, Migraine With Typical Aura, Migraine Disorders
Interventions
Dexamethasone, Lidocaine, Thiamine cohort
Combination Product
Lead sponsor
Corona Doctors Medical Clinics, Inc.
Other
Eligibility
10 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Corona, California
Completed Phase 4 Interventional Results available

Treximet in the Treatment of Chronic Migraine

NCT01090050
Conditions
Chronic Migraine
Interventions
Sumatriptan/Naproxen Sodium, Naproxen Sodium
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Springfield, Missouri • San Antonio, Texas